NCT01979510撤回3 期
A Phase III Randomized Clinical Trial to Evaluate the Safety and Efficacy of an Etoricoxib and Tizanidine Fixed Dose Combination in Subjects With Moderate to Severe Acute Low Back Pain
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 主要终点
- Number of Participants Experiencing an Adverse Event (AE)
研究概览
简要总结
The primary objective of this study is to evaluate the safety and tolerability of MK-0663B (etoricoxib/tizanidine) among participants with moderate-to-severe acute low back pain.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have acute low back pain;
- •Onset of acute low back pain must be <6 weeks prior to screening;
- •Have acute low back pain corresponding to a rating of ≥ 4 on a 0-10 point Low Back Pain Questionnaire and ≥ 7 on the Roland Morris Questionnaire;
- •For women of childbearing potential, have a negative serum pregnancy test at Visit 1 (Screening Visit) and agree to remain abstinent, use barrier, or non-hormonal implanted contraceptives from study start until 14 days after the last dose of study drug;
- •Be willing to limit alcohol use, if any, to 2 drinks or equivalent per day for the duration of the study and follow-up period;
- •Be willing to avoid unaccustomed physical activity (e.g., starting a new weight lifting routine) for the duration of the study and follow-up period;
- •Be willing to avoid chiropractic care, ultrasound and physical therapy from screening to Day 9;
- •Be willing to avoid cold applications and other alternate treatments (e.g. massage, acupuncture etc.) on Day 1 and within 30 minutes prior to scheduled pain assessments on Day 3 and Day 8.
排除标准
- •Has low back pain that is related to, or known to be caused by malignancy, inflammatory disease (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome), osteoporosis, ochronosis, vertebral fracture, infection, juvenile scoliosis, congenital malformation, or fibromyalgia. Note: the presence of radiographic degenerative disc disease is not an exclusion;
- •Has signs or symptoms consistent with a neurologic, infectious, or fracture-related cause of acute low back pain;
- •Has chronic low back pain and is experiencing an acute flare-up of the chronic back pain condition;
- •Has radicular or myelopathic pain;
- •Has a history of lumbar spine surgery;
- •Is involved in an active civil lawsuit or workman's compensation claim pertaining to his/her low back pain;
- •Has symptomatic depression that could interfere with the completion of the questionnaires;
- •Is mentally or legally incapacitated, has significant emotional problems at the time of the study, or has a history of major psychiatric disorder, including any history of psychosis;
- •Has a Body Mass Index (BMI) ≥ 40;
- •Is allergic to, or has a history of a significant clinical or laboratory adverse experience associated with tizanidine, etoricoxib, methocarbamol, meloxicam, or any non-steroidal anti-inflammatory drug (NSAID);
- •Is allergic to acetaminophen/paracetamol;
- •Is currently a user (including "recreational use") of any illicit drugs, or has a history (within 5 years) of drug or alcohol abuse;
- •Has participated in another investigational drug study within the last 4 weeks;
- •Has uncontrolled hypertension;
- •Has systolic blood pressure (SBP) < 105 or diastolic blood pressure (DBP) < 65;
- •Has a history of orthostatic hypotension;
- •Has ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease;
- •Has a positive human immunodeficiency virus (HIV) test result, hepatitis B surface (HBS) antigen, or hepatitis C virus (HCV) test result;
- •Has a history of hepatitis/hepatic disease that has been active within the previous year;
- •Has a history of gastric, biliary, or small intestinal surgery or disease that results in clinical malabsorption;
- •Has a history of neoplastic disease;
- •Has any personal or family history of an inherited or acquired bleeding disorder;
- •Is expected to undergo a planned surgical procedure or invasive diagnostic procedure during the course of the study;
- •Is pregnant or breast-feeding, or expecting to conceive within the projected duration of the study;
- •Has an active peptic ulcer or a history of inflammatory bowel disease.
研究组 & 干预措施
MK-0663B
Experimental
MK-0663B (etoricoxib 90 mg immediate release [IR]/tizanidine 6 mg modified release [MR]) capsules once daily for 8 days.
干预措施: MK-0663B (Drug)
MK-0663B
Experimental
MK-0663B (etoricoxib 90 mg immediate release [IR]/tizanidine 6 mg modified release [MR]) capsules once daily for 8 days.
干预措施: Acetaminophen 500 mg (Drug)
DOLOCAM PLUS®
Experimental
DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg) capsules once daily for 8 days.
干预措施: DOLOCAM PLUS® (Drug)
DOLOCAM PLUS®
Experimental
DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg) capsules once daily for 8 days.
干预措施: Acetaminophen 500 mg (Drug)
结局指标
主要结局
Number of Participants Experiencing an Adverse Event (AE)
时间窗: Up to Day 23
Number of Participants Discontinuing Study Treatment Due to an AE
时间窗: Up to Day 8
次要结局
- Proportion of Participants Using Rescue Medication During Study Treatment(Up to Day 8)
- Mean Change From Baseline in the Participant Roland Morris Disability Questionnaire(Baseline and Day 9)
- Mean Change From Baseline in the Participant Low Back Pain Questionnaire Score(Baseline and Day 9)
- Number of Participants With ≥30% Improvement From Baseline in the Roland Morris Disability(Baseline and Day 9)
- Mean Change From Baseline in the Investigator Global Assessment of Response to Therapy(Baseline and Day 9)
- Mean Change From Baseline in the Participant Global Assessment of Response to Therapy.(Baseline and Day 9)
- Average Amount of Rescue Medication Required by Participant During Study Treatment(Up to Day 8)
研究者
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)Cancer, AdvancedNCT00750178Merck Sharp & Dohme LLC30
已完成
3 期
Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With OsteoarthritisOsteoarthritis of the KneeNCT01554163Organon and Co239
已完成
2 期
An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)ObesityNCT00109148Merck Sharp & Dohme LLC500
已完成
3 期
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsCystic FibrosisNCT04537793Vertex Pharmaceuticals Incorporated83
已完成
1 期
[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)Alzheimer's DiseaseNCT02621606Merck Sharp & Dohme LLC20